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HUMAN CHROMOSOMES CONTAINING APOLIPOPROTEIN GENES

Cholesterol-Watching II: Genes
In a reception room at The Rockefeller University Hospital, a
patient watches a videotape. On it a doctor is speaking.
"You are now in the outpatient clinic of the laboratory of
biochemical genetics and metabolism. You are here because you
or someone in your family has a problem with elevated cholesterol or cholesterol imbalance. Your doctor may have described
your condition as hyperlipidemia, which means high levels of
lipid, or fat, in the blood."
The tape, written and narrated by Margo Denke, a member
of the laboratory's clinical staff, is a brief introduction to the role
of cholesterol in the development of atherosclerosis, one of the
thirty or so conditions under study in the hospital, which is
Rockefeller U niversitys clinical research center.
A drawing appears on the screen. Over the image, Dr.
Denkes voice continues: "Here is a picture of a normal artery.
Notice that the walls are thin and the opening is large. (The
picture begins to change shape.) In the process of atherosclerosis, a yellow, fatty deposit, primarily cholesterol, accumulates
on the inside of the artery making the walls thicker and the
opening smaller. Eventually this buildup may completely block
the opening and cut off the flow of blood. This permanently
damages the tissues and may lead to a heart attack or stroke."
As the tape progresses, the patient learns that cholesterol is
used by the body for making cell walls and hormones, that
about three quarters of it is manufactured in the body, mainly in
the liver, with the rest coming from cholesterol-containing
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food, and that excess cholesterol is excreted in stools or stored in
tissues and blood. He also learns that there are different kinds of
cholesterol, and that the ratio of "bad" to "good" cholesterol- of
LDL to HDL - is a much better predictor of risk for atherosclerosis than the toral amount of cholesterol in the blood stream; the
higher the LDL level, the greater the risk, the higher the HDL,
the lower the risk.
Cholesterol by itself is insoluble. In order to travel in the
blood it combines with proteins. This fat-protein package is
called a lipoprotein. The terms LDL and HDL are abbreviations
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Jonathan Smith, left, and
Sheldon Feinstein in the tissue
culture room where Ellen Johnson
tends lipoprotein-producing liver
cells.

for low-density lipoprotein and high-density lipoprotein, and
refer co their weight and size. At the present time, precise
measurements of LDL and HDL, and more refined measurements of the protein components of lipoproteins, can be done
only in research centers like Rockefeller. These and othet tests
our patient will undergo, plus the counseling he and his doceor
will receive from the hospital's researchers, nurses, and dietitians, will help him manage his condition in accordance with
the best insights currencly available co medical science. What he
will give in recurn is some genes.
The laboracory of biochemical genetics and metabolism is
under the leadership of Jan 1. Breslow, a 41-year-old pediacrician and biochemist crained at Columbia University and Harvard Medical School. Before coming co Rockefeller in January
1984, he worked at Harvard and the Children's Hospital Medical Center, in Boscon, for eleven years. Dr. Breslow is the latest
of a number of recent additions co the Rockefeller faculty,
invited co introduce new fields of investigation or new approaches in areas in which the University has traditionally been
strong, like cholesterol research. Edward H. Ahrens, Jr., the
subject of the first part of "Cholesterol-Watching" (Research
Profiles, Fall 1984), has spent most of the last forty years tracking
cholesterol through the body. Dr. Breslow is cracking the genes
that control lipoprotein struccure and function; in particular,
those that code for the production of apolipoproteins, the proteins that surround the cholesterol core in lipoproteins.

timebombs. Tennis champion Arthur Ashe had a heart accack in
his twenties and runner James Fixx died of one at fifty-two.
Genes and environment both playa role in the development
of atherosclerosis, bue, as Dr. Breslow points out, "in some
people it's obvious that heredity dominates, for bener or worse.
Since we know that one in ten American men can expece to have
a heart anack by the age of fifty-five, and of that group one in
three will die on the way co the hospital, or within a month
thereafter, we need to find the means to sort oue those who are
most susceptible and help them before they are stricken."
Dr. Breslow's interest in genetics and in diseases caused by
inborn errors of metabolism was direceed toward lipid research
after medical school during a postdoctoral stint at the National
Institutes of Health, where he worked in the laboratory of
Donald Frederickson, who formulated what is now the standard
system for classification of the hyperlipidemias. Invited back to
Harvard in 1973 to establish his own laboratory at Children's
Hospital, Dr. Breslow initiated the studies that this past September earned him the E. Mead Johnson Award, the major midcareer award of the American Academy of Pediacrics, for
"outstanding work in the area of the genetic basis of the lipoprotein disorders." His research, reads the citation, "has far-reaching implications as we begin to realize that atherosclerotic heart
disease has its beginnings in infancy and childhood."

ONE IN TEN BY FIFTY-FIVE
Researchers Li-Shin Huang,
left, and Hriday Das, with
assistant Jeffrey Levine tracking
apolipoprotein genes in the newly
completed molecular biology
laboratory.

How much is atherosclerosis a maccer of heredity and how much
environment? Epidemiological scudies have implicated a diet
high in animal fats, as well as obesity, inactivity, smoking, and
scress, among the faccors that can contribute co atherosclerosis
susceptibility. Although the recent crend coward a more prudent
life-style appears to be having a beneficial effece, heart disease,
most of it stemming from atherosclerosis, still accounts for half
the deaths in the United States. Yet, as we all know, there are
people who live high off the hog into their eighties and nineties
(what Dr. Breslow calls the Winston Churchill syndrome), and
there are seeming models of fitness whose vascular systems are

Dr. Breslow confers with fellow physicians, from left,
Moshe Weintraub, Elliot Brinton, and Margo Denke.
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APOLIPOPROTEINS
"There are several types of lipoprotein particles," Dr. Breslow
explains. "They differ in the amount of cholesterol they carry
and the types of apolipoproteins on their surface. LDL, which
normally comprises about two thirds of the total cholesterol in
the blood, is in charge of delivering cholesterol to cells. When a
cell needs cholesterol, molecular receptors on its surface 'recognize' and bind with LDL apolipoproteins, an action that allows
cholesterol to enter the cell. HDL acts as the cleanup squad that
removes cholesterol from tissue~ and begins the process of
transport to the liver for excretion in the bile."
In normal metabolic functioning, cholesterol from the diet
inhibits the synthesis of cholesterol in the liver so that the body
can maintain a healthy balance. In some early animal experiments in BostOn, Dr. Breslow discovered that a particle in the
blood that came from the intestines after cholesterol feeding,
and dramatically inhibited cholesterol synthesis, was very rich
in one particular apolipoprotein, apo E. "Apo E had only
recently been discovered," he says, "and we realized that if we
were going to understand our observation, as well as other
aspects of LDL and HDL regulation, we would have to make a
systematic study of apolipoproteins, including their geqes.
Fortunately, there were a number of people in the research
building where we worked, all investigating different diseases
but all, like us, needing to incorporate the new genetic technologies that were just becoming available. So we pooled our
resources and helped each other out. We learned as we went
along. "
Genes, which are made up of molecules of DNA, reside, in
multicellular organisms, within the nucleus of each cell on
structures called chromosomes. There are eight apolipoproteins,
designated A-I, A-II, A-IV, B, CI, CII, CIII, and E; and eight
genes that code for them. Dr. Breslow's laboratory was the first
to develop methods for cloning - making copies of - the DNA
of apolipoprotein genes. Mainly through his efforts, seven of the
eight apolipoprotein genes have been isolated, characterized,
and located on their specific chromosomes. The gene for apolipoprotein B, the major protein of LDL, has so far eluded
capture. Its cloning was one of the first projects Dr. Breslow
undertook with his new group at Rockefeller. "The preliminary
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Rearranged apo A-I and apo
ClII genes in patients with one
form of severe premature
atherosclerosis, as described on
page 4.
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results," he says, "look promising." Dr. Breslow was also the
first researcher to use DNA technology to understand human
disorders involving atherosclerosis.
"Working with apo E, we discovered that there are three
relatively common forms of the gene, resulting in six possible
patterns of the protein," Dr. Breslow relates. "We also discovered that patients with a condition called Type III hyperlipoproteinemia all have one particular pattern. This defective
form acrually occurs rather frequently in the general population, in about one in a hundred people, but the disease appears
in only a small percentage of that group. This finding led us to
suspect that an additional defect, in another gene, may be
necessary for hyperlipidemia to develop, and we're looking for
that second abnormality. We also think that the apo E or a
closely linked gene may have other, more widespread effects on
LDL cholesterol levels, which we're investigating.

, Annemarie Walsh, seated,
injects human apo A-I DNA
into the nucleus ofa fertilized
mouse egg. She will then
implant the egg in a female
mouse, Some of the offspring in
the resulting litter will carry the
human gene making it possible to
study the gene's activity.
Supervising is Elizabeth Lacy,
standing, Memorial SioanKettering Cancer Center
molecular biologist and one of the
pioneers in the development of
this technology.
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Roberto Taramel/i with
laboratory helper Katie Tsang.
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"When we started to look at the apolipoproteins for HDL we
again found an unexpected heterogeneity. Apo A-I is the major
protein of HDL. As we learned, apo A-I is made in one form
inside the cell and then undergoes a two-step modification
before it becomes the mature plasma form. The second step
occurs outside the cell in a process that seems to be unique to
this apolipoprotein. In studying patients with Tangier disease, a
rare condition in which HDL levels are extremely low, we
observed that most of the apo A-I in their blood was in a
precursor form. Now we're trying to find out whether this is due
to a structural defect or a defect in the converting activity.
"A particularly tantalizing finding came out of another study,
of a family referred to us in which there was an unusually high
incidence of severe premature atherosclerosis, and in which twO
sisters had had heart attacks in their twenties. These individuals
had extremely low HDL levels and lacked apo A-I and another
apolipoprotein, apo CUI, in their plasma. From our previous
work we knew that the genes for both these proteins are very
close to one another on the same chromosome. When we looked
at DNA samples from the sisters, we discovered that part of the
apo CUI gene had left its proper position and become inserted
into the apo A-I gene. This DNA rearrangement had inactivited
both the apo A-I and the apo CUI genes. It's pretty awesome to
think of a single gene abnormality that can accelerate the age for
a heart attack by fifty years.
"About five percent of the population has half-normal HDL
[evels. Having demonstrated in a protOtype situation that a
lesion in the apo A-I gene was the cause, we're very eager to find
out if that or similar apo A-I gene lesions might be an explanation for the general phenomenon."

A LABORATORY IS BORN
It's been a hectic year for Dr. Breslow, recruiting a research team,
house-hunting for his family, and overseeing the monumental
task of transforming the seventh floor of the Rockefeller Hospital to accommodate molecular technology and his own six-footfour-inch frame. By next summer, when all the members of the
laboratory have finally arrived from around the country and the
world, they will number about twenty-five, including support
staff.

"They're a terrific group," says Dr. Breslow, "Hriday Das, a
molecular biologist from Yale, who's working on the organization of human apolipoprotein genes, has recently discovered
that the gene for apo CI resides very close to the apo E gene.
Sheldon Feinstein, from Yale and the Weizmann Institute, is
looking ar the expression of the apo A-I gene. Roberto Taramelli, who came from Italy via the Medical Research Council,
in England, is cloning apolipoprotein genes from patients with
lipoprotein disorders to determine the nature of the DNA
defect. Jonathan Smith, a new Ph.D. from Harvard, is studying
apo E expression in human liver-cell cultures. Li-Shin Huang is
an immunologist who joined us from the University of Delaware. She's applying immunological techniques to clone the
gene for apo B. Annemarie Walsh, a nucleic acid chemist,
trained at New York University and worked at the University of
Michigan. Shes going to see ifby introducing the human apo AI gene into the germline of an atherosclerosis-susceptible mouse
she can turn it into a resistant one. This system, which she's
learning from colleagues across the street at Memorial SloanKettering Cancer Center, will also allow us to study the function
of other apolipoproteins.
"There are three M.D.s in the lab in addition to myself. Dr.
Denke, who's just finished her clinical residency at Brigham and
Womens Hospital, is concerned with the nutritional aspects of
atherosclerosis. Besides being the star of our orientation tapes,
she's involved in studies of LDL metabolism and the development of an immunoassay for ~po B. Elliot Brinton is an endocrinologist. He came from a three-year fellowship in Seattle
during which he defined cellular receptOrs for HDL. He's now
looking at HDL rumover in patients with coronary artery
disease. Moshe Weintraub is a cardiologist from Israel who has
been in clinical practice for a number of years and is interested in
learning research techniques. He's applying the methods we
established in Boston for identifying the six types of apo E to
examining their role in the metabolism of dietary fat."
The patients who come to Dr. Breslows clinic may not know
much about genetics or the apolipoprotein alphabet. "What
they do know," he says, "is that we take a lot of blood from
them." They also know that within the DNA in those blood
cells may lie the key to their children's future health.

